NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization12.75 mln
Float6.40 mln
Earnings Date08/07/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
5.00
Transformational upside
Relative Strength
21
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-68.49
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Chemomab Therapeutics is an Israeli medical research company working to develop new treatments for serious conditions that cause inflammation and scarring in the body's tissues and organs. Its primary drug, nebokitug, targets a specific protein called CCL24, which plays a key role in driving these harmful processes. The company has tested nebokitug in two mid-stage clinical trials, focusing on patients with primary sclerosing cholangitis and systemic sclerosis.
